miRNAs as Evaluation Biomarker of Tuberculosis Treatment Response

Asif Mohammed from the International Centre for Genetic Engineering and Biotechnology in India will identify miRNA patterns as potential biomarkers as per Receiver Operating Characteristics, to identify quantitative patterns of circulating human miRNAs which can be used as early biomarkers to predict outcome of the anti-TB drug therapy. They will follow-up patients during their course of treatment with first line anti-TB drugs, and will isolate, sequence, identify and quantitate circulating miRNAs in sputum and plasma of these individuals at one month, two month and 6/9 months of treatment.